Thousand Oaks biotech Atara Biotherapeutics announced an $80 million net loss, or $1.75 per share, in the fourth quarter of 2018, missing analyst estimates of $1.31 and sending shares tumbling 15 percent in early trading Feb. 26. The company reported a 151 percent increase in research and development costs to $62.3 million in the fourth…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
